Literature DB >> 31712271

Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Age-Period-Cohort Analysis.

Xiaotao Zhang1,2, Hashem B El-Serag3, Aaron P Thrift4,2.   

Abstract

BACKGROUND: Incidence rates for hepatocellular carcinoma (HCC) vary considerably by age, sex, and race/ethnicity. We assessed whether the underlying reasons for variations in HCC among subgroups of the population by age, sex, race/ethnicity, and birth cohort are uniform or whether they interact with one another or have changed over time.
METHODS: Data were from the U.S. Cancer Statistics registry. We assessed annual trends within population subgroups and examined for secular trends in the male-to-female ratio for HCC incidence. We used joinpoint regression to compute annual percent change and average annual percent change (AAPC) and corresponding 95% confidence intervals (CI). We also used age-period-cohort models to disentangle period and cohort effects.
RESULTS: Between 2001 and 2015, HCC rates increased in men and women ≥50 years, remained stable among women ages 40 to 49 years, but decreased among males ages 40 to 44 years (AAPC = -2.47%; 95% CI, -3.15% to -1.80%) and 45 to 49 years (AAPC = -3.49%; 95% CI, -4.78% to -2.17%). As a result, the male-to-female incidence rate ratio (IRR) among persons aged <50 years decreased from 4.63 in 2001 to 2.42 in 2015 but remained stable over time among persons aged ≥50 years. HCC rates were lower among successive cohorts of males born after circa 1956, whereas HCC rates among females born circa 1991 were higher than those among females born circa 1956 (IRR = 1.67; 95% CI, 1.05-2.65).
CONCLUSIONS: As a result of decreasing incidence among males aged <50 years and strong cohort effect, the epidemiology of HCC is changing from a disease with striking male predominance to one with less male predominance. IMPACT: The sex and racial disparities and strong birth cohort effect on HCC risk identified in this study have important implications for population-based HCC prevention efforts. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2019        PMID: 31712271     DOI: 10.1158/1055-9965.EPI-19-1052

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  10 in total

1.  Emissions of dioxins and dioxin-like compounds and incidence of hepatocellular carcinoma in the United States.

Authors:  Trang VoPham; Kimberly A Bertrand; Jared A Fisher; Mary H Ward; Francine Laden; Rena R Jones
Journal:  Environ Res       Date:  2021-11-17       Impact factor: 6.498

2.  Gender, Age, Racial and Ethnic Disparities in Clinical Trial Enrollment for Primary Liver Cancer.

Authors:  Jenny Jan; Azeez Osho; Caitlin C Murphy; Carolyn M Mazure; Amit G Singal; Nicole E Rich
Journal:  Gastroenterology       Date:  2022-03-12       Impact factor: 33.883

3.  Racial and Sex Disparities in Hepatocellular Carcinoma in the USA.

Authors:  Faith Ajayi; Jenny Jan; Amit G Singal; Nicole E Rich
Journal:  Curr Hepatol Rep       Date:  2020-11-12

Review 4.  Epidemiology of Hepatocellular Carcinoma.

Authors:  Katherine A McGlynn; Jessica L Petrick; Hashem B El-Serag
Journal:  Hepatology       Date:  2020-11-24       Impact factor: 17.298

5.  NAFLD and MAFLD as emerging causes of HCC: A populational study.

Authors:  Shuna Myers; Isabelle Neyroud-Caspar; Laurent Spahr; Konstantinos Gkouvatsos; Evelyne Fournier; Emiliano Giostra; Giulia Magini; Jean-Louis Frossard; Marie-Eve Bascaron; Nathalie Vernaz; Lucia Zampaglione; Francesco Negro; Nicolas Goossens
Journal:  JHEP Rep       Date:  2021-01-19

6.  Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic.

Authors:  Angela Y Jia; Aleksandra Popovic; Aditya A Mohan; Jane Zorzi; Paige Griffith; Amy K Kim; Robert A Anders; Richard A Burkhart; Kelly Lafaro; Christos Georgiades; Nilofer S Azad; Robert P Liddell; Marina Baretti; Ihab R Kamel; Amol Narang; Mark Yarchoan; Jeffrey Meyer
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

7.  Association between socioeconomic status and survival in patients with hepatocellular carcinoma.

Authors:  Yongshun Zheng; Xun Zhang; Jinsen Lu; Shuchen Liu; Yeben Qian
Journal:  Cancer Med       Date:  2021-08-20       Impact factor: 4.452

8.  The Impact of Socioeconomic Status on Staging, Prognosis in Hepatocellular Carcinoma.

Authors:  Yongjie Zhou; Wen Zhang; Jingqin Ma; Zihan Zhang; Minjie Yang; Jianjun Luo; Zhiping Yan
Journal:  Int J Gen Med       Date:  2022-02-15

9.  Developing a prediction model for estimating adrenocorticotropic hormone changes in patients undergoing scheduled open hepatectomy.

Authors:  Yu Guan; Jie Tang; Jiali Yu; Yiqi Zhu; Ailun Li; Fang Fang; Jing Cang
Journal:  Ann Transl Med       Date:  2022-06

10.  The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt.

Authors:  Dina Sweed; Enas Sweed; Inas Moaz; Asmaa Mosbeh; Yahya Fayed; Sara Mohamed Abd Elhamed; Eman Sweed; Mahmoud Macshut; Shimaa Abdelsattar; Shimaa Kilany; Sara A Saied; Reda Badr; Mahmoud S Abdallah; Nermine Ehsan
Journal:  World J Surg Oncol       Date:  2022-09-19       Impact factor: 3.253

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.